A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Inclusion Criteria: 1. Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not amenable to curative treatment (such as with surgery and/or radiation) 2. CPS≥1 3. Has measurable disease per RECIST 1.1 as assessed by IRRC 4. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 14 days prior to randomization 5. Has adequate organ function Exclusion Criteria: 1. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. 3. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis 4. Has an active infection requiring systemic therapy 5. Has a known history of human immunodeficiency virus (HIV) infection 6. Has received prior therapy with an anti-PD-1, anti-PD-L1 or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4）